2.1. Study Design, Conduct and Treatment
hormone-sensitive prostate cancer
HORMONE-SENSITIVE PROSTATE CANCER
Five clinical trials were conducted at investigational sites in Lithuania and Latvia between 2004 and 2007 with each trial testing a different loading dose and/or regimen of teverelix DP in patients with advanced, hormone-sensitive prostate cancer (All studies were conducted in accordance with the current version of the Declaration of Helsinki and with favorable opinion from the competent authority and independent ethics committee for each investigational site (Teverelix DP was supplied as a freeze-dried powder without any excipient, which was reconstituted with 5% mannitol (